Corvus Pharmaceuticals Inc Stock
A very strong showing by Corvus Pharmaceuticals Inc today, with an increase of €0.22 (3.510%) compared to yesterday's price.
Corvus Pharmaceuticals Inc is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 10 € there is a hugely positive potential of 54.08% for Corvus Pharmaceuticals Inc compared to the current price of 6.49 €.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 0 users see the criterium "Brand" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "Brand" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | 3.510% | 1.724% | -14.040% | 38.675% | 33.539% | 734.297% | 104.088% |
| Ardelyx Inc. | -1.890% | 1.234% | -3.978% | 11.858% | -0.826% | 131.663% | -14.721% |
| ImmunityBio Inc. | -7.110% | 0.281% | -2.591% | -30.552% | -35.518% | -64.290% | -87.635% |
| Krystal Biotech | 0.850% | 4.672% | 13.930% | 39.043% | 41.327% | 190.676% | - |
Comments
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Mizuho from $12.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $17.00 price target on the stock, up previously from $15.00.
Show more
Ratings data for CRVS provided by MarketBeat
News
Corvus (CRVS) Q2 Loss Beats Estimates
Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies, released its earnings results for Q2 2025 on August 7, 2025
